Prashanth Gopalakrishna

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Srđan Verstovšek, Jason Gotlib, Ruben A. Mesa et al. · Journal of Hematology & Oncology · 2017 · 298 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

David M. Ross, Tamás Masszi, María Teresa Gómez‐Casares et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 141 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

Linda T. Vahdat, Agustin A. García, Charles L. Vogel et al. · Breast Cancer Research and Treatment · 2013 · 67 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

Sarah P. Blagden, Anne Hamilton, Linda Mileshkin et al. · Clinical Cancer Research · 2018 · 66 citations · Full text

Medicine, Oncology, Pharmacology +17

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

Mary Frances McMullin, Claire Harrison, Dietger Niederwieser et al. · Experimental Hematology and Oncology · 2015 · 41 citations · Full text

Medicine, Hematology, Pharmacology +12